Skip to main content
SpringerLink
Log in

Phosphodiesterase 4 (PDE4) gene expression in atopic dermatitis patients, before and after treatment with topical mometasone cream

  • Investigative Report
  • Published:
European Journal of Dermatology

Abstract

Background

Atopic dermatitis (AD) is a chronic pruritic inflammatory dermatosis. Phosphodiesterases (PDEs) are a superfamily of enzymes that catalyse the hydrolysis of cyclic AMP (cAMP), a second messenger that controls key cellular functions, into its inactive forms. Selective inhibitors of PDE4, a cAMP-specific PDE, serve as potent antiinflammatory agents.

Objectives

To measure PDE4 gene expression in patients with AD before and after treatment with topical mometasone cream, in comparison to controls.

Materials & Methods

Twenty patients with acute and subacute AD were investigated. Skin biopsies before and after treatment were obtained for evaluation of PDE4 expression level by RT-PCR.

Results

The level of PDE4 mRNA was significantly higher in AD patients either before or after treatment compared to controls (p < 0.001), and the level of PDE4 mRNA in AD patients significantly decreased following treatment (p < 0.001).

Conclusion

Our study indicates that there is an increased level of PDE4 in AD lesions, suggesting that PDE4 plays an important role in the pathogenesis of AD. Targeting PDE4 (using PDE4 inhibitors) may herald a new era in the treatment of AD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Boulos S, Yan AC. Current concepts in the prevention of atopic dermatitis. Clin Dermatol 2018; 36: 668–71.

    Article  PubMed  Google Scholar 

  2. Simpson EL, Irvine AD, Eichenfield LF, et al. Update on epidemiology, diagnosis and disease course of atopic dermatitis. Semin Cutan Med Surg 2016; 35: S84–8.

    Article  Google Scholar 

  3. Hong J, Buddenkotte J, Berger TG. Management of itch in atopic dermatitis. Semin Cutan Med Surg 2011; 30: 71–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Chang Y-S, Chiang B-L. Mechanism of sleep disturbance in children with atopic dermatitis and the role of the circadian rhythm and melatonin. Int J Mol Sci 2016; 17: 462.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Hanifin JM, Chan SC. Monocyte phosphodiesterase abnormalities and dysregulation of lymphocyte function in atopic dermatitis. J Invest Dermatol 1995; 105: 84S–8S.

    Article  CAS  PubMed  Google Scholar 

  6. Houslay MD, Miles D, David RA. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J 2003; 370: 1–18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Ahmad F, Murata T, Simizu K, Degerman E, Maurice D, Manganiello V. Cyclic nucleotide phosphodiestrases: important signaling modulators and therapeutic targets. Oral Dis 2015; 21: e25–50.

    Article  CAS  PubMed  Google Scholar 

  8. Arellano FM, Arana A, Wentworth CE, et al. Lymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United Kingdom. J Allergy Clin Immunol 2009; 123: 1111–6, 116.e1–13.

    Article  CAS  PubMed  Google Scholar 

  9. Hanifin JM, Chan SC, Cheng JB, et al. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Investig Dermatol 1996; 107: 51–6.

    Article  CAS  PubMed  Google Scholar 

  10. Levy J, Zhou DM, Zippin JH. Cyclic adenosine monophosphate signaling in inflammatory skin disease. J Clin Exp Dermatol Res 2016; 7: 326–32.

    Google Scholar 

  11. Udkoff J, Waldman A, Ahluwalia J, et al. Current and emerging topical therapies for atopic dermatitis. Clin Dermatol 2017; 35: 375–82.

    Article  PubMed  Google Scholar 

  12. Kunz BIF, Ring J. Clinical features and diagnostic criteria of atopic dermatitis. In: Harper J, Oranje A, Prose N, editors. Textbook of pediatric dermatology (2nd edition). Oxford: Blackwell, 2006, p. 227–44.

    Google Scholar 

  13. Leung DY. Atopic dermatitis: new insights and opportunities for therapeutic intervention. J Allerg Clin Immunol 2000; 105: 860–76.

    Article  CAS  Google Scholar 

  14. Samrao A, Berry TM, Goreshi R, et al. A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults. Arch Dermatol 2012; 148: 890–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Volf E, Au S, Dumont N, et al. A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis. J Drugs Dermatol 2012; 11: 341.

    CAS  PubMed  Google Scholar 

  16. Furue M, Kitahara Y, Akama H, Hojo S, Hayashi N, Nakagawa H. Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis: Results of a randomized, vehicle-controlled, multicenter clinical trial. J Dermatol 2014; 41: 577–85.

    Article  CAS  PubMed  Google Scholar 

  17. Andoh T, Kuraishi Y. Antipruritic mechanisms of topical E6005, a phosphodiesterase 4 inhibitor: inhibition of responses to proteinase-activated receptor 2 stimulation mediated by increase in intracellular cyclic AMP. J Dermatol Sci 2014; 76: 206–13.

    Article  CAS  PubMed  Google Scholar 

  18. Hanifin JM, Ellis CN, Frieden IJ, et al. OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): a phase-II randomized, doubleblind, placebo-controlled study. J Am Acad Dermatol 2016; 75: 297–305.

    Article  CAS  PubMed  Google Scholar 

  19. Zane LT, Chanda S, Jarnagin K, Nelson DB, Spelman L, Gold LS. Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies. Immunotherapy 2016; 8: 853–66.

    Article  CAS  PubMed  Google Scholar 

  20. Eichenfield LF, Call RS, Forsha DW, et al. Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis. J Am Acad Dermatol 2017; 77(4): 641–9.e5.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dermatology Department, Kasr Alainy Medical school (faculty of Medicine), Cairo University, Cairo, Egypt

    Hanan Rabea Nada, Jamila Shehada & Pakinam I. N. Mostafa

  2. Biochemistry Department, Kasr Alainy Medical School (Faculty of medicine), Cairo University, Cairo, Egypt

    Laila Ahmed Rashed

Authors
  1. Hanan Rabea Nada
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laila Ahmed Rashed
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jamila Shehada
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pakinam I. N. Mostafa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pakinam I. N. Mostafa.

Additional information

Financial support

none.

Conflicts of interest

none.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nada, H.R., Rashed, L.A., Shehada, J. et al. Phosphodiesterase 4 (PDE4) gene expression in atopic dermatitis patients, before and after treatment with topical mometasone cream. Eur J Dermatol 32, 19–23 (2022). https://doi.org/10.1684/ejd.2022.4194

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1684/ejd.2022.4194

Key words

Search

Navigation